Longitudinal, Nationwide, Cohort Study to Assess Incidence, Outcomes, and Costs Associated With Complicated Urinary Tract Infection

被引:12
作者
Carreno, Joseph J. [1 ]
Tam, Iris M. [2 ]
Meyers, Juliana L. [3 ]
Esterberg, Elizabeth [3 ]
Candrilli, Sean D. [3 ]
Lodise, Thomas P., Jr. [1 ]
机构
[1] Albany Coll Pharm & Hlth Sci, Pharm Practice, 106 New Scotland Ave, Albany, NY 12208 USA
[2] Achaogen Inc, San Francisco, CA USA
[3] RTI Hlth Solut, Res Triangle Pk, NC USA
来源
OPEN FORUM INFECTIOUS DISEASES | 2019年 / 6卷 / 11期
关键词
burden; cUTI; epidemiology; outcomes; urinary tract infection; EMERGENCY-DEPARTMENT; ACUTE PYELONEPHRITIS; OPTIMIZATION; TAZOBACTAM; PROGRAM;
D O I
10.1093/ofid/ofz446
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Objective. Complicated urinary tract infections (cUTI) are common infections. Despite their frequency, limited data are available on the incidence and healthcare burden associated with cUTIs. This study details the epidemiology and 30-day health care resource utilization associated with cUTI in the United States. Method. This was a retrospective study of a PharmMetrics Plus database from January 1, 2013, to December 31, 2017. Inclusion criteria were as follows: age =18 years, International Classification of Diseases (Ninth or Tenth revision) cUTI diagnosis, and continuous enrollment for =6 months pre- and =30 days post index dates. Two mutually exclusive study cohorts for cUTI patients were identified based on the setting of the first observed cUTI diagnosis (inpatient [IP] and outpatient [OP]). Results. In total, 543 502 adults with cUTI met the inclusion criteria (104 866 IP cohort; 438 636 OP cohort). Mean (standard deviation) age was 48.1 (16.5) years and 68.1% were female. The overall incidence of cUTI was 1.01%, equating to approximately 2 882 195 annual cUTI cases in the United States. In the IP cohort, overall median (interquartile range [IQR]) 30-day health care costs were $13 028 ($4855-$26 781). Median (IQR) costs for the initial admission were $9441 ($2079-$19 027), with median (IQR) length of stay (LOS) of 4 (3-8) days. Among IP patients, 12 933 (12.3%) had a subsequent readmission. In the OP cohort, median (IQR) 30-day health care costs were $1531 ($305-$4998). Of OP patients, 40 457 (9.2%) had a 30-day admission. Conclusions. This study demonstrates that the economic burden associated with cUTIs is substantial, especially among patients requiring hospitalization. These findings highlight the need for new treatment approaches and antibiotics that avert hospitalization and reduce LOS.
引用
收藏
页数:11
相关论文
共 23 条
  • [1] Optimization of antibiotic selection in the emergency department for urine culture follow ups, a retrospective pre-post intervention study: clinical pharmacist efforts
    Almulhim, Abdulaziz Saleh
    Aldayyen, Ali
    Yenina, Kateryna
    Chiappini, Adam
    Khan, Tahir Mehmood
    [J]. JOURNAL OF PHARMACEUTICAL POLICY AND PRACTICE, 2019, 12 (01)
  • [2] Acute pyelonephritis among adults - Cost of illness and considerations for the economic evaluation of therapy
    Brown, P
    Ki, M
    Foxman, B
    [J]. PHARMACOECONOMICS, 2005, 23 (11) : 1123 - 1142
  • [3] Ceftazidime-avibactam or best available therapy in patients with ceftazidime-resistant Enterobacteriaceae and Pseudomonas aeruginosa complicated urinary tract infections or complicated intra-abdominal infections (REPRISE): a randomised, pathogen-directed, phase 3 study
    Carmeli, Yehuda
    Armstrong, Jon
    Laud, Peter J.
    Newell, Paul
    Stone, Greg
    Wardman, Angela
    Gasink, Leanne B.
    [J]. LANCET INFECTIOUS DISEASES, 2016, 16 (06) : 661 - 673
  • [4] A NEW METHOD OF CLASSIFYING PROGNOSTIC CO-MORBIDITY IN LONGITUDINAL-STUDIES - DEVELOPMENT AND VALIDATION
    CHARLSON, ME
    POMPEI, P
    ALES, KL
    MACKENZIE, CR
    [J]. JOURNAL OF CHRONIC DISEASES, 1987, 40 (05): : 373 - 383
  • [5] Connolly LE, 2018, ANTIMICROB AGENTS CH, V62, DOI [10.1128/AAC.01989-17, 10.1128/aac.01989-17]
  • [6] Pharmacist-driven antimicrobial optimization in the emergency department (Reprinted from Journal of Health-System Pharmacy Residents JHPR, vol 2, issue 1, 2013)
    Davis, Lucretia C.
    Covey, Robin B.
    Weston, Jaye S.
    Hu, Bee Bee Y.
    Laine, Gregory A.
    [J]. AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2016, 73 (05) : S49 - S56
  • [7] Impact of a Multidisciplinary Culture Follow-up Program of Antimicrobial Therapy in the Emergency Department
    Dumkow L.E.
    Kenney R.M.
    MacDonald N.C.
    Carreno J.J.
    Malhotra M.K.
    Davis S.L.
    [J]. Infectious Diseases and Therapy, 2014, 3 (1) : 45 - 53
  • [8] Pharmacist-led antimicrobial stewardship program in an urgent care setting
    Fay, Lauren N.
    Wolf, Lauren M.
    Brandt, Kasey L.
    DeYoung, G. Robert
    Anderson, Adam M.
    Egwuatu, Nnaemeka E.
    Dumkow, Lisa E.
    [J]. AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2019, 76 (03) : 175 - 181
  • [9] Gupta K, 2011, CLIN INFECT DIS, V52, pE103, DOI [10.1093/cid/cir102, 10.1093/cid/ciq257]
  • [10] Effect of Meropenem-Vaborbactam vs Piperacillin-Tazobactam on Clinical Cure or Improvement and Microbial Eradication in Complicated Urinary Tract Infection The TANGO I Randomized Clinical Trial
    Kaye, Keith S.
    Bhowmick, Tanaya
    Metallidis, Symeon
    Bleasdale, Susan C.
    Sagan, Olexiy S.
    Stus, Viktor
    Vazquez, Jose
    Zaitsev, Valerii
    Bidair, Mohamed
    Chorvat, Erik
    Dragoescu, Petru Octavian
    Fedosiuk, Elena
    Horcajada, Juan P.
    Murta, Claudia
    Sarychev, Yaroslav
    Stoev, Ventsislav
    Morgan, Elizabeth
    Fusaro, Karen
    Griffith, David
    Lomovskaya, Olga
    Alexander, Elizabeth L.
    Loutit, Jeffery
    Dudley, Michael N.
    Giamarellos-Bourboulis, Evangelos J.
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2018, 319 (08): : 788 - 799